Research programme: 11-beta hydroxysteroid dehydrogenase inhibitors - Johnson & JohnsonAlternative Names: JNJ 25918646
Latest Information Update: 11 Sep 2008
At a glance
- Originator Johnson & Johnson
- Class Adamantanes
- Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity